Diploma (LON:DPLM – Get Free Report) had its price objective raised by equities research analysts at Deutsche Bank Aktiengesellschaft from GBX 6,400 to GBX 7,200 in a note issued to investors on Wednesday,London Stock Exchange reports. The firm currently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential upside of 6.19% from the stock’s previous close.
Other equities research analysts have also issued research reports about the stock. Shore Capital Group reissued a “hold” rating on shares of Diploma in a report on Wednesday, March 18th. Berenberg Bank lifted their target price on shares of Diploma from GBX 7,500 to GBX 9,000 and gave the company a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. upped their target price on shares of Diploma from GBX 5,120 to GBX 5,760 and gave the company a “neutral” rating in a research note on Friday, March 27th. Royal Bank Of Canada increased their price target on shares of Diploma from GBX 6,600 to GBX 7,300 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Stifel Nicolaus raised their price target on shares of Diploma from GBX 6,200 to GBX 6,800 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Diploma presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 6,626.25.
Read Our Latest Stock Report on Diploma
Diploma Price Performance
Diploma (LON:DPLM – Get Free Report) last issued its earnings results on Tuesday, May 19th. The company reported GBX 74.70 EPS for the quarter. The business had revenue of £851.10 million during the quarter. Diploma had a return on equity of 14.17% and a net margin of 8.99%. As a group, equities analysts expect that Diploma will post 163.7995512 EPS for the current year.
Insider Transactions at Diploma
In related news, insider Ian El-Mokadem acquired 500 shares of the company’s stock in a transaction on Friday, March 20th. The stock was purchased at an average cost of GBX 5,820 per share, for a total transaction of £29,100. 1.14% of the stock is owned by corporate insiders.
Trending Headlines about Diploma
Here are the key news stories impacting Diploma this week:
- Positive Sentiment: Diploma lifted growth guidance again after reporting strong first-half results, suggesting momentum is continuing into the second half. Diploma Shares Surge as Strong First-Half Results Trigger Another Guidance Upgrade (DPLM)
- Positive Sentiment: Royal Bank of Canada raised its price target on Diploma to GBX 7,300 from GBX 6,600 and reiterated an outperform rating, signaling improved confidence from analysts. Digital Look broker views
- Positive Sentiment: Berenberg also increased its target to GBX 9,000 from GBX 7,500 and maintained a buy rating, adding to the bullish analyst backdrop. Digital Look broker views
- Positive Sentiment: Coverage highlighting Diploma as a growth compounder and the strong controls division performance may be supporting investor enthusiasm for the stock. Diploma lifts growth guidance (again)
- Neutral Sentiment: The company’s reported quarterly results showed revenue of £851.1 million and EPS of GBX 74.70, which were broadly consistent with the upbeat guidance narrative. Diploma PLC earnings report
- Neutral Sentiment: Analysts’ consensus price target of about GBX 6,251 suggests some estimates still lag the newer, more optimistic broker targets. Diploma PLC receives GBX 6,251.25 consensus PT from analysts
Diploma Company Profile
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Read More
- Five stocks we like better than Diploma
- Strategy Inc. Buys Bitcoin and Eyes a Dividend Amid Market Fear
- Vertical Aerospace: Pre-Flight Checks Point to a Breakout
- Palo Alto Networks Up 70%: Can the Rally Last Into June?
- Block’s Pivot to Profits and AI Is Turning Heads
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.
